Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a systematic review and meta-analysis to clarify the relationship between ICT and long-term survival in patients with MDS. A total of 14 studies involving 7242 participants were identified; the outcomes revealed that for patients with MDS, ICT resulted in a lower risk of mortality compared to those with no ICT (HR 0.57; 95% CI 0.44-0.70; P < 0.001); what is more, ICT led to a lower risk of leukemia transformation (HR 0.70; 95% CI 0.52-0.93; P = 0.016). Results of subgroup analyses based on adequate ICT or any ICT, low/int-1 IPSS or unclassified IPSS and study types indicated that the ICT had a beneficial role in all these groups of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, a randomized study and meta‐analysis clarified that patients who were assigned to an ICT group showed longer survival, with low risk of progression to leukemia, compared with a non‐ICT group.42, 43”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [43]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120 · cited 1×
“The present meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines [24, 25].”
MethodRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., Olivieri, N., Piga, A., Cunningham, M. J., Soulières, D., et al. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00985.x · Cited by 237
Rose, C., Brechignac, S., Vassilief, D., Pascal, L., Stamatoullas, A., Guerci, A., Larbaa, D., Dreyfus, F., Beyne-Rauzy, O., Chaury, M. P., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.12.004 · Cited by 195 · cited 1×
“Rose [27] 2010 France 72 55/42 97 (53/44) Pro 45/52/0/0”
Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.009 · Cited by 173
List, A. F., Baer, M. R., Steensma, D. P., Raza, A., Esposito, J., Martinez-Lopez, N., Paley, C., Feigert, J., & Besa, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1222 · Cited by 172
Gattermann, N., Finelli, C., Della Porta, M., Fenaux, P., Stadler, M., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.048546 · Cited by 168
Neukirchen, J., Fox, F., Kündgen, A., Nachtkamp, K., Strupp, C., Haas, R. R., Germing, U., & Gattermann, N. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.006 · Cited by 136
Ghoti, H., Amer, J., Winder, A., Rachmilewitz, E., & Fibach, E. (2007) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00972.x · Cited by 109
Angelucci, E., Santini, V., Tucci, A. A. D., Quaresmini, G., Finelli, C., Volpe, A., Quarta, G., Rivellini, F., Sanpaolo, G., Cilloni, D., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12300 · Cited by 103
Iron overload in myelodysplastic syndromes (MDS)
Gattermann, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2367-1 · Cited by 96
Lu, W., Zhao, M., Rajbhandary, S., Xie, F., Chai, X., Mu, J., Meng, J., Liu, Y., Jiang, Y., Xu, X., et al. (2013) · European Journal of Haematology · doi:10.1111/ejh.12159 · Cited by 86
Nolte, F., Höchsmann, B., Giagounidis, A. A. N., Lübbert, M., Platzbecker, U., Haase, D. T., Luck, A. A., Gattermann, N., Taupitz, M., Baier, M. L., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1594-z · Cited by 83
Deferasirox for managing iron overload in people with thalassaemia
Bollig, C., Schell, L. K., Rücker, G., Allert, R., Motschall, E., Niemeyer, C. M., Bassler, D., & Meerpohl, J. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007476.pub3 · Cited by 76
Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy
Leitch, H. A., Leger, C. S., Goodman, T. A., Wong, K. K., Wong, D. H. C., Ramadan, K. M., Rollins, M. D., Barnett, M. J., Galbraith, P. F., & Vickars, L. M. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.026 · Cited by 76
Mainous, A. G., Tanner, R. J., Hulihan, M., Amaya, M. P., & Coates, T. D. (2014) · British Journal of Haematology · doi:10.1111/bjh.13053 · Cited by 66 · cited 2×
“In recent years, several new studies with larger sample size and better design have been reported; therefore, a new meta-analysis is needed to evaluate the application value of ICT in MDS, including high IPSS score [23].”
BackgroundResultDelforge, M., Selleslag, D., Beguin, Y. P., Triffet, A., Mineur, P., Theunissen, K., Graux, C., Trullemans, F., Boulet, D., Eygen, K. V., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.003 · Cited by 66 · cited 1×
“Delforge [32] 2014 USA 71/73 56/71 127 (80/47) Retro 54/73/0/0”
Leitch, H. A., Parmar, A., Wells, R. A., Chodirker, L., Zhu, N. Y., Nevill, T. J., Yee, K. W. L., Leber, B. F., Keating, M., Sabloff, M., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14825 · Cited by 65
On behalf of the IRON-2 Study Group, Remacha, A. F., Arrizabalaga, B., Villegas, A., Durán, M. S., Hermosín, L., de Paz, R., García, M., Díez‐Campelo, M., & Sanz, G. F. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2274-y · Cited by 63
Jabbour, E. J., Takahashi, K., Wang, X., Cornelison, A. M., Abruzzo, L. V., Kadia, T. M., Borthakur, G. M., Estrov, Z. E., O'Brien, S. M., Mallo, M., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23513 · Cited by 54
Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome
Chung, Y. J., Robert, C., Gough, S. M., Rassool, F. V., & Aplan, P. D. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.07.008 · Cited by 53
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mitchell, M., Gore, S. D., & Zeidan, A. M. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.814456 · Cited by 52
Lyons, R. M., Marek, B. J., Paley, C. S., Esposito, J., Garbo, L. E., DiBella, N. J., & Garcia‐Manero, G. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.11.004 · Cited by 46 · cited 1×
“Lyons [31] 2014 USA 75/72 347/253 600 (263/337) Pro 112/181/0/0”
Zeidan, A. M., Hendrick, F. B., Friedmann, E., Baer, M. R., Gore, S. D., Sasané, M., Paley, C. S., & Davidoff, A. J. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.20 · Cited by 45
Raptis, A., Duh, M. S., Wang, S., Dial, E., Fanourgiakis, I., Fortner, B., Paley, C. S., Mody‐Patel, N., Corral, M., & Scott, J. W. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02361.x · Cited by 42
Angelucci, E., Li, J., Greenberg, P. L., Depei, W., Hou, M., Figueroa, E. H. M., Rodriguez, G., Dong, X., Ghosh, J., Bornstein, O., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111134 · Cited by 39
Zeidan, A. M., Giri, S., DeVeaux, M., Ballas, S. K., & Duong, V. H. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3539-7 · Cited by 38
Karami, H., Kosaryan, M., Amree, A. H., Darvishi‐Khezri, H., & Mousavi, M. (2017) · Clinics and Practice · doi:10.4081/cp.2017.912 · Cited by 35
Pileggi, C., Sanzo, M. D., Mascaro, V., Marafioti, M. G., Costanzo, F. S., & Pavía, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179016 · Cited by 35
To chelate or not to chelate in MDS: That is the question!
Zeidan, A. M., & Griffiths, E. A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.03.002 · Cited by 34
Gonçalves, A. C., Cortesão, E., Oliveiros, B., Alves, V., Espadana, A. I., Rito, L., Magalhães, E., Pereira, S., Pereira, A., Costa, N., et al. (2015) · Clinical and Experimental Medicine · doi:10.1007/s10238-015-0357-2 · Cited by 31
Komrokji, R. S., Ali, N. H. A., Padron, E., Lancet, J. E., & List, A. F. (2011) · Blood · doi:10.1182/blood.v118.21.2776.2776 · Cited by 30
Sanctis, V. D. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.064 · Cited by 30
Leitch, H. A., Buckstein, R. J., Zhu, N. Y., Nevill, T. J., Yee, K. W. L., Leber, B. F., Keating, M., St‐Hilaire, È., Kumar, R., Delage, R., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.09.005 · Cited by 27
Waszczuk‐Gajda, A., Mądry, K., Machowicz, R., Drozd-Sokolowska, J. E., Stella-Holowiecka, B. M., Mital, A., Obara, A., Szmigielska‐Kapłon, A., Sikorska, A., Subocz, E., et al. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/62397 · Cited by 25
Maurillo, L., Breccia, M., Buccisano, F., Voso, M. T., Niscola, P., Trapè, G., Tatarelli, C., D’Addosio, A., Latagliata, R., Fenu, S., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12476 · Cited by 24 · cited 1×
“5% among patients, mainly gastrointestinal and renal toxicity [41].”
BackgroundThe deleterious effects of iron overload in patients with myelodysplastic syndromes
Dreyfus, F. (2008) · Blood Reviews · doi:10.1016/s0268-960x(08)70006-7 · Cited by 24
Kattamis, A., Aydınok, Y., & Taher, A. T. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13111 · Cited by 24
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
Carreau, N. A., Tremblay, D. A., Savona, M. R., Kremyanskaya, M., & Mascarenhas, J. O. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.04.003 · Cited by 21
Langemeijer, S. M. C., de Swart, L., Yu, G., Smith, A., Crouch, S., Johnston, T., Fenaux, P., Symeonidis, A. S., Čermák, J., Hellström‐Lindberg, E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.3186.3186 · Cited by 20
Myelodysplasia and Good syndrome. A case report
Renzo, M. D., Pasqui, A. L., Voltolini, L., Gotti, G., Pompella, G., & Auteri, A. (2008) · Clinical and Experimental Medicine · doi:10.1007/s10238-008-0175-x · Cited by 11
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong, S. A., & Leitch, H. A. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.11.005 · Cited by 10
Abraham, I. L., Yami, M. S. A., Yun, S., Kim, H., Vincelette, N. D., McBride, A., & MacDonald, K. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.03.007 · Cited by 9
Shammo, J. M., & Komrokji, R. S. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1486188 · Cited by 9
Gray, A., Litinas, E., Hoppensteadt, D., Cunanan, J., Lewis, B., Iqbal, O., & Fareed, J. (2011) · Blood · doi:10.1182/blood.v118.21.1196.1196 · Cited by 7
Cited by
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae
Kim, C. H., & Leitch, H. A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103367 · Cited by 56
Iron overload and its impact on outcome of patients with hematological diseases
Franke, G., Kubasch, A. S., Cross, M. A., Vučinić, V., & Platzbecker, U. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100868 · Cited by 43
Complement activation and coagulopathy - an ominous duo in COVID19
Tomo, S., Kumar, K. P., Roy, D., Sankanagoudar, S., Purohit, P., Yadav, D., Banerjee, M., Sharma, P., & Misra, S. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1875813 · Cited by 31
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
Palumbo, G. A., Galimberti, S., Barcellini, W., Cilloni, D., Renzo, N. D., Elli, E. M., Finelli, C., Maurillo, L., Ricco, A., Musto, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752192 · Cited by 21
Metadata
- Authors
- Liu, H., Yang, N., Meng, S., Zhang, Y., Zhang, H., & Zhang, W.
- Affiliations
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Corresponding author
- Zhang, Wanggang
- Venue
- Clinical and Experimental Medicine
- Published
- 2019-11-11
- Volume
- 20
- Issue
- 1
- Pages
- 1-9
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- OpenAlex
- W2988761910
- Cited by
- 13
- References
- 47
- Citations by year
- 2025: 3 · 2023: 1 · 2021: 6 · 2020: 3
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical and Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Shaanxi International Scientific Research Cooperation and Exchange Program (2016KW-020)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- iron chelation therapy, myelodysplastic syndrome, iron overload, blood transfusion, mortality, leukemic transformation, long-term survival, International Prognostic Scoring System, subgroup analysis
- MeSH terms
- Humans, Iron, Myelodysplastic Syndromes, Chelation Therapy, Survival Analysis, Treatment Outcome, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.